Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Evolus Inc.

Division of Alphaeon Corp.
www.evolus.com

Latest From Evolus Inc.

Finance Watch: Panic Over FDA Commissioner's Resignation Was Short-Lived, Though IPOs Still Languish

Public Company Edition: Biotech stocks sank when US FDA Commissioner Scott Gottlieb announced his departure, but have nearly recovered to pre-resignation levels, except for newly public firms. Also, Biohaven's raises cash for PRV purchase and Endo issues $1.5bn in new debt.

Deals Financing

Another Botox Competitor: Revance Prepares Longer-Lasting RT002 For BLA Submission

A claim that RT002's duration of efficacy surpasses the leading neurotoxin – Allergan's blockbuster Botox – will be put to the test when Revance seeks US FDA approval to treat frown lines in the first half of this year. The company's Botox biosimilar with Mylan also could move forward in 2019.

Aesthetics Business Strategies

Keeping Track: CDER Approves Its First Two Novel Agents Of 2019

The latest drug development news and highlights from our US FDA Performance Tracker.
Drug Review Regulation

With Jeuveau Approval, Evolus Will Focus On The Beauty Business To Gain Market Share

Evolus believes its focus on the beauty business will be a differentiator for its neurotoxin Jeuveau. The company will publish head-to-head results against Botox alongside the Spring 2019 launch and does not expect a new trade secrets complaint from Botox maker Allergan to delay its product.

Approvals Launches
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Alphaeon Corp.
  • Senior Management
  • David Moatazedi, Pres. & CEO
    Lauren Silvernail, CFO & EVP, Corp. Dev.
    J. Christopher Marmo, PhD, COO
    Rui Avelar, MD, Head, R&D & CMO
    Michael Mazen Jafar, Chief Mktg. Officer
  • Contact Info
  • Evolus Inc.
    Phone: (949) 284-4555
    520 Newport Center Dr.
    Ste. 1200
    Newport Beach, CA 92660
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register